Szerző szerinti böngészés "Halasi, Barbara Dora"
Megjelenítve 1 - 4 (Összesen 4)
Találat egy oldalon
Rendezési lehetőségek
Tétel Korlátozottan hozzáférhető Pharmacologial Aspects of Metabolic Syndrome.Jo, Sua; Pórszász, Róbert; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklósi, József András; Halasi, Barbara Dora; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Debreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetThe thesis discusses mainly about the metabolic syndrome and its subcategories. The subcategories consists of Insulin Resistance, Central Obesity, Hypertension and Dyslipidemia. The thesis first briefly mention the etiologies and risk factors, symptoms, diagnosis but focuses mainly on the treatment, especially emphasizing the pharmacological drugs. When discussing about the pharmacological aspects of the diseases, it is written based on their mechanisms of action, contraindications, and adverse effects. Finally, the thesis further goes through the intimate relationships between these diseases showing how they affects each other and the common indications of their drugs.Tétel Korlátozottan hozzáférhető Pharmacology of Banned Performance-Enhancing DrugsBaltinester, Noam; Pórszász, Róbert; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Halasi, Barbara Dora; Szentmiklósi, József András; Debreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetPerformane-enhancing drugs, aka PEDs, are a grouping of several classes of drugs which are known to enhance athletic performance and are therefore their use has been baned. This thesis explored the pharmacology of a handful of PEDs. Making use of various studies, case reports, and litterature reviews, we looked into the pharmacokinetics, pharmacodynamics, and adverse effects of various PEDs, as well as some other aspects of their use. Along with this, a brief history of PED use as well as ethical and legal aspects were discussed.Tétel Korlátozottan hozzáférhető Prevention And Pharmacological Management Of ArrythmiaAhmad, Mostafa; Porszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Halasi, Barbara Dora; Szentmiklósi, József; Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetThis paper discusses arrhythmias and their myriad of causes. Topics such as incidence and prevalence in the population are also discussed. Global patterns and future trends are mentioned in regards to arrhythmia. The treatment for arrhythmia whether it be conservative or pharmacological is also mentioned. The different types of medication is distinguished in the discussion of the topic.Tétel Korlátozottan hozzáférhető The role of SSRIs in the treatment of unipolar depressionHaji Heidari Varnousafaderani, Mahsa; Pórszász, Róbert; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklósi, József András; Halasi, Barbara Dora; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Debreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetThe therapeutic indications for SSRIs, adverse effect profiles, variations among classes, and possible associations with SI were all covered in this study. SSRIs were first used to treat depressive disorders, such as unipolar depression, but they are now also used to treat anxiety disorders, other mental illnesses, and a few physical ailments. Depending on the comorbidities, genetics, and probable side effects of the patient, each SSRI has distinct qualities which render it a better match for certain persons. Patients who require multiple pharmacologic treatments for various conditions may benefit from considering an SSRI like citalopram or escitalopram that does not inhibit cytochrome P450 enzymes, as this can help prevent potential drug-drug interactions. Although SSRIs are far more well tolerated than MAOIs and TCAs that came before them, there are still some possible side effects. A few of the most typical ones include sexual dysfunction, GI discomfort, sleeplessness, and irritability. The black box warning for a higher probability of SI in children and young people aged 18 to 24 is one of the most contentious side effects of SSRIs. The intricacies and interactions of SSRIs in a depressed young person's growing brain are poorly understood. Adults without particular risk characteristics, as previously mentioned, do not seem to be at elevated risk of suicidality. In the end, a risk-benefit analysis must take the possible effects of the condition to be treated, side effects, and risks into account before prescribing SSRIs to any patient.